About 80% of pediatric T-ALL patients showed higher levels of β-catenin compared to healthy controls, which leads to aberrant activation of β-catenin-dependent genes, including C-MYC, BIRC5, TCF1, and LEF [79,80]. The gene discussed is MYC; the disease is acute lymphoblastic leukemia.